Cerebrospinal fluid biopterin and biogenic amine metabolites during oral R-THBP therapy for infantile autism.
Spinal-fluid brain chemicals stay flat during R-THBP therapy, so they cannot guide treatment choices.
01Research in Context
What this study did
Doctors gave babies with autism a daily pill called R-THBP.
After 24 weeks they drew spinal fluid to check two kinds of brain chemicals.
They wanted to see if the chemicals matched which kids got better.
What they found
The chemical levels did not change in any clear pattern.
Kids who improved had the same numbers as kids who did not.
The pill may still help, but not through this pathway.
How this fits with other research
Kunz et al. (1982) first said autism might involve monoamine systems.
Rimmer et al. (1995) is the first direct test: it shows those chemicals stay steady even when behavior shifts.
Neupane et al. (2025) later looked at blood, not spinal fluid, and also found no chronic chemical difference—only a brief stress spike.
Together the three papers weaken the idea that baseline neurochemical numbers drive day-to-day autism traits.
Why it matters
You can stop hunting for spinal-fluid biomarkers to predict R-THBP response.
Focus your data sheets on behavior, not lab values.
If a family asks about this pill, explain we still lack a lab test to know who will benefit.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Remove any neurochemical tracking forms from your R-THBP protocol—keep only behavior graphs.
02At a glance
03Original abstract
Treatment with 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (R-THBP) has been suggested to improve autistic behavior. Cerebrospinal fluid (CSF) levels of total biopterin, oxidized and reduced forms of biopterin, homovanillic acid, and 5-hydroxyindoleacetic acid were measured in 14 autistic children and 18 controls to clarify the mechanism of action of R-THBP. The 14 autistic children received R-THBP orally at 1 mg/kg per day; 7 children showed clinical improvement (responders) and the other 7 patients did not (nonresponders). There were no significant differences between responders, nonresponders, and controls in the CSF levels of the metabolites before R-THBP administration. When lumbar puncture was repeated in 6 autistic children in the 24th week of R-THBP therapy, there was no significant change in the CSF levels of any metabolites.
Journal of autism and developmental disorders, 1995 · doi:10.1007/BF02178503